Thus, we aimed to investigate whether the cross-talk between TPL2/MEK/ERK pathway and PDE4D/cAMP signaling mediates the antitumor effect of IFN-α and the potential of these molecules as biomarkers for targeted molecular therapy of bladder cancer. The gene discussed is MAP3K8; the disease is urinary bladder carcinoma.